Efficacy and safety of <scp>PD</scp>‐1 monoclonal antibody combined with interferon‐alpha 1b and anlotinib hydrochloride as the second‐line therapy in patients with unresectable advanced melanoma: A retrospective study
PD-1 monoclonal antibody plus interferon-alpha 1b plus anlotinib showed acceptable tolerability and anticancer benefits in Chinese metastatic melanoma patients as a second-line therapy.
Authors
- Tianwen Gao (ORCID: https://orcid.org/0000-0002-8621-8611)
- Guannan Zhu (ORCID: https://orcid.org/0000-0002-2980-0074)
- Fang Liu (ORCID: https://orcid.org/0000-0002-0046-8434)
- Chunying Li (ORCID: https://orcid.org/0000-0003-3004-5376)
- Mengyu Zhang (ORCID: https://orcid.org/0000-0001-9375-6664)
- Jingyi Tang
- Bolun Zhao (ORCID: https://orcid.org/0000-0002-2377-5795)
- Qiong Shi (ORCID: https://orcid.org/0000-0003-3588-462X)
- Daopei Zou (ORCID: https://orcid.org/0000-0001-8312-7178)
Institutions
- Xijing Hospital (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1002/cam4.70087
- Citations
- 4
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- National Natural Science Foundation of China